Compare Ginkgo Bioworks Holdings Inc (DNA) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Nutanix Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while Nutanix Inc trades at $64.31 (market cap $17.39B). The key difference: Nutanix Inc is far larger — about 34.4× Ginkgo Bioworks Holdings Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | NTNX | |
|---|---|---|
Market Cap | $505.73M | $17.39B |
Sector | Health | Technology |
52-Week High | $16.14 | $81.12 |
52-Week Low | $5.48 | $34.41 |
Enterprise Value | $607.68M | $16.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Nutanix (NTNX) trades at $64.32, down 0.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.47 surpassing the $0.36 expectation. Revenue grew to $2.54B in 2025 with a net income margin of 7.42%, while 2026 projections show improved profitability. Analyst sentiment remains positive with 20 buy ratings and a $57.80 consensus price target.
The outlook for NTNX is supported by strong earnings momentum and institutional interest, though high valuation multiples (P/E 67.71) and supply chain risks noted in recent news pose challenges. The stock's proximity to resistance at $65.00 suggests near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
